Epidural Steroid Injections Do Not Worsen Long-Term Outcomes in Lumbar Disc Herniation
Epidural steroid injections (ESIs) do not worsen long-term outcomes for patients with lumbar disc herniation—they provide short-to-medium term pain relief without causing harm to eventual outcomes, though their benefits diminish over time and do not prevent the need for surgery in many patients.
The Evidence on Long-Term Outcomes
The most recent and highest-quality evidence comes from the 2025 BMJ clinical practice guideline, which provides a strong recommendation in favor of fluoroscopically-guided epidural injections (with or without steroids) for chronic spine pain associated with disc herniation 1. This guideline acknowledges small risks of moderate-to-serious harms (deep infection, altered consciousness) and very small risks of catastrophic complications (paralysis, death), but these do not constitute "worsening" of the underlying disc herniation pathology.
What Actually Happens Long-Term
The research paints a clear picture of natural disease progression rather than treatment-induced deterioration:
High recurrence rates are the norm, not a consequence of ESI: A 5-year follow-up study found that 76.9% of patients experienced recurrent pain after initial ESI, but only 23.1% had current pain at 5 years, and just 7.7% were unemployed due to pain 2. Critically, when comparing patients who eventually had surgery versus those who didn't, there were no differences in rates of recurrent pain, current pain, opioid use, or unemployment status.
ESI doesn't prevent surgery but doesn't worsen surgical candidacy: In the SPORT trial subgroup analysis, patients who received ESI had similar 4-year outcomes compared to those who didn't receive injections 3. The ESI group had higher crossover from surgical to nonsurgical treatment (41% vs 12%), but this was confounded by baseline preference to avoid surgery, not treatment failure.
Short-to-medium term benefits are real: A 2024 meta-analysis demonstrated significant pain relief at 3 months (MD = 0.44) and 6 months (MD = 0.66), with reduced opioid usage (MD = -14.45) 4. A 2025 meta-analysis confirmed transforaminal ESI showed the greatest pain reduction at 3 months (NRS improvement of -5.15) 5.
The Critical Distinction: Temporary Relief vs. Disease Modification
ESIs provide symptomatic relief without altering the underlying disc pathology—this is not "worsening" outcomes, it's simply not curing the disease. The 2025 evidence synthesis of 72 RCTs involving 7,701 patients confirms that ESI surpasses other conservative methods for treating sciatica but does not provide long-term disease modification 6.
When ESI Becomes Problematic
The only documented scenario where ESI truly worsens outcomes is when it delays necessary surgery in patients with progressive neurological deficits. One case report described a patient with massive L2-L3 disc herniation who received 3 unnecessary ESIs over 3 months, ultimately developing cauda equina syndrome 7. This represents misuse of the intervention, not an inherent property of ESI to worsen disc herniation.
Clinical Algorithm for ESI Use
Use ESI when:
- Radicular pain from confirmed disc herniation on imaging
- No progressive motor weakness or cauda equina symptoms
- Failed conservative therapy (NSAIDs, physical therapy)
- Patient preference to avoid or delay surgery
Do NOT use ESI when:
- Progressive neurological deficits present
- Cauda equina syndrome suspected
- Massive disc herniation with severe canal compromise
- Pure axial back pain without radiculopathy (strong recommendation AGAINST per 2025 BMJ guideline) 1
Approach selection:
- Transforaminal ESI shows superior outcomes for disc-related radiculopathy 5, 6
- Use fluoroscopic or ultrasound guidance (superior to blind injection) 6
Important Caveats
Expect symptom recurrence: Long-term studies show pain often returns by 6-12 months 8, 2, 9. This reflects the natural history of disc disease, not treatment failure.
Functional improvement lags behind pain relief: ESI provides better pain reduction than functional improvement measured by ODI/RMDQ scores 4.
Patient factors matter: A 2026 study found that central canal stenosis, disco-osteophyte abnormalities, chronic symptoms, and female sex predicted less favorable outcomes 10. Extruded discs required more repeat injections than protruded discs 8.
Multiple injections delay definitive care: Repeated ESIs without improvement should prompt surgical evaluation, not additional injections. The 2025 BMJ guideline notes patients may need injections every 2 weeks to 3 months if perceived effective 1.
The Bottom Line on "Worsening"
There is no evidence that ESI accelerates disc degeneration, increases herniation size, or worsens surgical outcomes when surgery eventually becomes necessary. The appearance of "worsening" in clinical practice reflects either: (1) natural disease progression that would occur regardless of treatment, or (2) inappropriate patient selection where ESI delays needed surgery in patients with surgical indications.